Tumour Profiling using Next Generation Sequencing (NGS)

Helen Roberts (Bevan Exemplar)
Michelle Wood (Clinical Scientist)
drianne Davies (Genetic Technologist)
Matt Lyon (Bioinformatician)

Cardiff and Vale University Health Board with Industry Partner, Antony Harris (Qiagen)

The project aims to use our existing staff knowledge and experience of Next Generation Sequencing (NGS) to validate the Qiagen GeneRead Tumour Actionable Mutations panel for the analysis of Formalin-Fixed Paraffin-Embedded solid tumour samples. This tumour profiling will direct treatment options for patients based on the presence/absence of specific genetic mutations within the tumour. Such genetic analysis is currently performed using a less sensitive technology, thus this technology transfer ensures that an increased number of patients will potentially gain access to stratified medicine.

This Project Supports Prudent Healthcare

Achieve health and well-being:

Effective use of resources:

Do no harm:


Anticipated Outcomes